For owners
Selling to an MSO vs a private buyer
Federal and state law current as of September 2026 — verify with counsel.
A multi-state operator usually offers a larger headline price, but in 2025 and 2026 very little of it was paid in cash at closing. A private buyer, such as a regional operator or investor group, usually offers less, with more cash and a seller note, and often needs more help with regulator approval. Compare offers on cash at close and the risk of everything else.
Key takeaways
- Cash was under 2% of disclosed cannabis M&A consideration in 2025, according to Viridian Capital data reported by Forbes in January 2026.
- Vireo Growth's four December 2024 acquisitions were all stock, priced at about 4.2x to 5.4x reference EBITDA, with 33-month lock-ups and clawbacks.
- Public MSOs with market caps above $100 million traded at a median 5.1x EV to 2026 EBITDA in November 2025, which limits what they can pay for a single store.
- State ownership caps can disqualify an MSO outright: Illinois limits any owner to 10 dispensary licenses.
- A smaller cash offer can be worth more than a larger stock offer once lock-ups, clawbacks, and thin trading are priced in.
MSO buyer vs private buyer at a glance
| Factor | Multi-state operator (MSO) | Private buyer |
|---|---|---|
| Who they are | Public or large private groups operating in several states | Regional operators, single-state groups, family offices, investor groups, managers |
| What they want | Stores or capacity that fill a gap in a state where they already operate; limited-license markets | A profitable business they can run; sometimes a first licence in a new state |
| Typical consideration | Shares, notes, earn-outs, some cash | More cash as a share of price, plus a seller note |
| Headline price | Often higher | Often lower |
| Certainty of value | Lower when stock is a large share | Higher if the cash is proven and the note is secured |
| Diligence | Heavy, run by a deal team; long request lists | Varies widely; first-time buyers can be slow |
| Approval risk | Licence caps, many disclosed parties, public-company changes of plan | Buyer eligibility, source-of-funds review, inexperience with the regulator |
| After closing | Brand and systems replaced; owner usually exits after a short transition | Brand and staff more likely kept; owner may be asked to stay longer |
How MSOs are paying in 2025 and 2026
Mostly not in cash. Data from Viridian Capital, reported by Forbes in January 2026, put cash at under 2% of disclosed cannabis deal consideration in 2025.
The most active public acquirer of the period shows the pattern. In December 2024 Vireo Growth announced four acquisitions worth about $397 million, all in stock at a reference price of $0.52 per share. Three were priced at 4.175x reference EBITDA and one at about 5.4x. Sellers accepted 33-month staggered lock-ups, earn-outs tied to 2026 performance, and clawbacks if EBITDA fell short. Its July 2026 agreement to buy Planet 13 was also a share exchange, conditional on stockholder, exchange, and state cannabis approvals.
Small deals show more cash but still a mix. In June 2026 TerrAscend agreed an option to buy a New Jersey dispensary for $9 million, split $6 million cash and a $3 million convertible note, and Vireo Growth closed on a 49% Maryland dispensary stake for $1.55 million, paid with $400,000 cash, a $400,000 note, and $750,000 in shares.
What stock consideration really means for you, including lock-ups and tax, is covered in selling for MSO stock. The three payment forms are compared in cash vs stock vs seller note.
Why can an MSO sometimes pay more?
An MSO can pay more when your business is worth more in its hands. It can remove duplicate overhead, buy inventory at scale, and sell its own products through your store at a higher margin. In a capped state, your licence may be the only way to add a location.
There is a ceiling. Public MSOs with market caps above $100 million traded at a median 5.1x enterprise value to 2026 EBITDA in November 2025. A public buyer struggles to justify paying a higher multiple for your business than the market gives its own shares, especially when it pays in those shares. Current private-deal ranges are in dispensary valuation multiples.
Not every MSO is a strong buyer. Several large operators restructured debt or exited states in 2025 and 2026. A buyer under pressure from lenders may sign a letter of intent and then fail to close. Read the buyer’s latest quarterly filing before you grant exclusivity. The consolidation picture is in MSOs and consolidation.
What do private buyers offer instead?
Private buyers usually offer more certainty per dollar and less price. A typical private offer is cash at close plus a seller note, sometimes with a short earn-out. Banks and the SBA do not fund plant-touching acquisitions, so the buyer’s cash comes from equity partners or private lenders, and the gap is filled by you. The mechanics are in seller financing in cannabis deals.
The risks are different:
- Proof of funds. Ask for it before you open the data room, not after.
- Eligibility. A first-time buyer may not know the state’s residency, background, or financial-disclosure rules. A regulator rejection months in costs you the season. See ownership eligibility, background checks, and residency.
- Note risk. If the buyer runs the business badly, your note suffers. You generally cannot take the licence back without regulator approval.
Private buyers are often better for staff and brand continuity. Many want the owner to stay for a handover period and keep the name on the door.
Regulatory approval differs by buyer type
Every buyer needs ownership-change approval, but the friction points are different.
MSOs run into caps. Illinois, for example, limits any owner to 10 dispensary licences, and several other states cap stores or canopy per owner. An MSO at its cap cannot buy you at any price. Public companies must also disclose officers, directors, and large holders, which lengthens the file. State-by-state limits are in ownership caps and residency rules by state.
Private buyers run into source-of-funds review. Regulators want to see every person behind the money, which can be uncomfortable for passive investors. See true party of interest and financial interest rules.
Social equity licences often cannot be sold to an MSO at all during a holding period.
Comparing two offers: an illustrative example
Illustrative only. A dispensary earns $1.0 million of normalised EBITDA.
| MSO offer | Private offer | |
|---|---|---|
| Headline price | $5.0 million (5.0x) | $4.0 million (4.0x) |
| Cash at close | $1.0 million | $2.8 million |
| Seller note | $1.0 million, unsecured, 3 years | $1.2 million, secured by equity pledge, 4 years |
| Stock | $3.0 million, locked up 12 to 33 months | None |
| Seller’s haircut | Note at 80%, stock at 50% | Note at 85% |
| Risk-adjusted value | $1.0m + $0.8m + $1.5m = $3.3 million | $2.8m + $1.02m = $3.82 million |
The haircuts are judgement calls, not market data. Change the stock discount to 80% and the MSO offer wins. The point is to do the arithmetic in the open. A seller who believes in the acquirer’s shares and does not need the cash may rationally take the MSO deal. A seller retiring on the proceeds usually should not.
Which buyer fits which seller?
An MSO buyer tends to fit when:
- You hold a licence in a capped state where the MSO already operates.
- You have multiple locations or meaningful scale.
- You can hold stock for two to three years and tolerate a fall in its price.
- You want a clean exit with a short transition.
A private buyer tends to fit when:
- You operate a single store or a mid-size grow in an open or competitive market.
- You need most of the value in cash.
- Staff and brand continuity matter to you.
- You are willing to carry a note and stay involved through a handover.
You do not have to choose in advance. A confidential process that approaches both groups at once, under NDA, is the usual way to find out what each will really pay. How that works is set out in selling a cannabis business confidentially. This page is educational, not legal, tax, or investment advice.
Frequently asked questions
Do MSOs still buy single dispensaries?
Yes, selectively. Public filings in 2026 show MSOs buying single stores and minority stakes for amounts in the low millions, usually in limited-license states where the store fills a gap in an existing footprint. They rarely enter a new state for one store, and they rarely pay all cash. Expect a mix of cash, a note, and shares.
Will an MSO pay more than a private buyer?
Often on paper, not always in value. An MSO may be able to justify a higher multiple because it can cut overhead and push its own brands through your shelves. But if half the price is locked-up stock or an earn-out, the risk-adjusted value can be lower than a private buyer's cash-and-note offer. Compare the offers line by line, not by headline.
Is regulatory approval easier with an MSO buyer?
The filing is usually cleaner because an MSO has compliance staff and owners who have been vetted before. The risk is different, not smaller. MSOs can hit state license caps, public-company disclosure rules add parties to the application, and a large buyer may walk away if its own financing or strategy changes during a long approval wait.
What kinds of private buyers purchase cannabis businesses?
Regional operators adding a store or a grow, single-state groups moving toward vertical integration, family offices and private investor groups, out-of-state operators entering a new market, and sometimes the seller's own managers. Each has a different ability to pay cash and a different learning curve with the regulator.
Can I ask an MSO buyer for all cash?
You can ask, and a well-capitalised buyer may agree for a small, strategic asset. Deal data from 2025 shows cash was a very small share of total consideration across the sector, so an all-cash demand narrows the field. A more realistic goal is to maximise cash at close and secure or shorten everything that is deferred.
Sources
- Forbes (Javier Hasse) — Cannabis M&A Didn't Vanish. It's Just Not Happening In Public (20 January 2026) — https://www.forbes.com/sites/javierhasse/2026/01/20/cannabis-ma-didnt-vanish-its-just-not-happening-in-public/
- New Cannabis Ventures — Vireo Growth to Acquire 4 Cannabis Companies (18 December 2024) — https://www.newcannabisventures.com/vireo-growth-acquires-4-cannabis-companies/
- Highly Capitalized — Viridian Capital Advisors Reports Valuation Metrics for U.S. MSOs with Market Caps Above $100M (18 November 2025) — https://highlycapitalized.com/viridian-capital-advisors-reports-valuation-metrics-for-u-s-msos-with-market-caps-100m/
- TerrAscend — TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey (30 June 2026) — https://ir.terrascend.com/news-events/press-releases/detail/285/terrascend-signs-agreement-to-acquire-fifth-dispensary-in-new-jersey
- Vireo Growth — Vireo Growth Inc. Completes Acquisition of Equity Interest in Maryland Dispensaries (18 June 2026) — https://www.globenewswire.com/news-release/2026/06/18/3314519/0/en/Vireo-Growth-Inc-Completes-Acquisition-of-Equity-Interest-in-Maryland-Dispensaries.html
- SEC EDGAR — Vireo Growth Inc. Form 8-K, Exhibit 99.1: Vireo Growth to Acquire Planet 13 Holdings (27 July 2026) — https://www.sec.gov/Archives/edgar/data/0001771706/000110465926086874/tm2621363d1_ex99-1.htm
- Illinois Department of Financial and Professional Regulation — Change of Ownership Guidance (7 February 2023) — https://idfpr.illinois.gov/content/dam/soi/en/web/idfpr/forms/auc/2023-2-7-change-of-ownership-guidance.pdf
- Akerman LLP — Rescheduled but Not Listed: The Outlook for U.S. Cannabis Companies on Major Exchanges (14 May 2026) — https://www.akerman.com/en/perspectives/rescheduled-but-not-listed-the-outlook-for-us-cannabis-companies-on-major-exchanges.html